On the morning of Thursday, March 7, the House Ways & Means Committee’s Subcommittee on Health held a hearing titled Promoting Competition to Lower Medicare Drug Prices. The hearing focused a great deal on the effect of patents in the pharmaceutical industry as they relate to pricing. Although some of the Republican membership of the subcommittee pointed out issues with various proposals to limit patent protections for drugmakers, the panel acted largely as a firing squad for patents. In his closing statement, Rep. Doggett expressed his dissatisfaction with the tenor of the day’s debate. “I view it as encouraging that there is bipartisan recognition of the serious problems so many Americans are facing with, really, prescription price gouging,” he said. “The question is whether we’ll have any bipartisan agreement on doing anything about it.”
The post House Health Subcommittee Holds Fractious Hearing on Drug Pricing and Patent Protections appeared first on IPWatchdog.com | Patents & Patent Law.
Recent Posts
- Cellspin Attempt at Recusal in Case Against Fitbit Falls Flat at CAFC
- Other Barks & Bites for Friday, November 1: USCO Grants Right to Repair Copyright Exemption to Restaurants; EU Hits Teva with $503 Million Fine for Misusing Patent System; and Former USPTO Director Andrei Iancu Endorses Trump
- CAFC Affirms Several PTAB Findings that Centripetal’s Network Security Patent Claims are Obvious
- Perlmutter Gets Pressure from Congress to Release AI Reports
- Life Sciences Masters Panelists Say USPTO’s Controversial Anti-Pharma Rules are Unlikely to Progress